Clinical Trial Update: Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) [Phase 4]

View source ↗

Summary

Phase 4 trial update comparing durability of insulin-GLP-1 RA or SGLT-2 inhibitors combination versus basal-bolus insulin in type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Snippet

Sponsor: University of Campania Luigi Vanvitelli | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED